Abstract: An example embodiment may involve (i) receiving, by a server device, deoxyribonucleic acid (DNA) information associated with a user; (ii) parsing, by the server device, the DNA information to identify one or more single nucleotide polymorphisms (SNPs); (iii) determining, by the server device and based on the identified SNPs, an endocannabinoid genotype of the user; (iv) determining, based on the endocannabinoid genotype of the user, a recommendation of one or more cannabinoid formulations; (v) transmitting, to a client device associated with the user, a web-based representation of a first graphical user interface; and (vi) receiving, from the client device, an indication to display a detailed representation of a particular cannabinoid formulation of the one or more cannabinoid formulations.

Abstract: The disclosure is directed to formulations comprising cannabinoids. More particularly, the cannabinoid formulations can be designed to align with an individual's genotype based on a defined list of polymorphisms.

Abstract: An example embodiment may involve (i) receiving, by a server device, deoxyribonucleic acid (DNA) information associated with a user; (ii) parsing, by the server device, the DNA information to identify one or more single nucleotide polymorphisms (SNPs); (iii) determining, by the server device and based on the identified SNPs, an endocannabinoid genotype of the user; (iv) determining, based on the endocannabinoid genotype of the user, a recommendation of one or more cannabinoid formulations; (v) transmitting, to a client device associated with the user, a web-based representation of a first graphical user interface; and (vi) receiving, from the client device, an indication to display a detailed representation of a particular cannabinoid formulation of the one or more cannabinoid formulations.

Abstract: The invention relates to methods and kits for treating and/or diagnosing Cannabinoid hyperemesis syndrome (CHS) in a patient or for predicting propensity for or resistance to CHS in a cannabis user.

Abstract: An example embodiment may involve (i) receiving, by a server device, deoxyribonucleic acid (DNA) information associated with a user; (ii) parsing, by the server device, the DNA information to identify one or more single nucleotide polymorphisms (SNPs)—(iii) determining, by the server device and based, on the identified SNPs, an endocannabinoid genotype of the user; (iv) determining, based on the endocannabinoid genotype of the user, a recommendation of one or more cannabinoid formulations; (v) transmitting, to a client device associated with the user, a web-based representation of a first graphical user interface; and (vi) receiving, from the client device, an indication to display a detailed representation of a particular cannabinoid formulation of the one or more cannabinoid formulations.

Abstract: Examples disclosed herein may involve a computing system that is configured to (i) identify a cannabinoid formulation for which to model efficacy for a given health condition shared by a plurality of individuals, (ii) receive respective efficacy information indicating the efficacy of the cannabinoid formulation for the plurality of individuals, (iii) receive respective genetic information for the plurality of individuals, (iv) receive respective biometric information for the plurality of individuals, (v) apply machine learning techniques to group the plurality of individuals into one or more groups based on their (a) respective efficacy information and (b) similarities in their respective genetic information and respective biometric information, and (vi) embody the one or more groups into a machine learning model that functions to (a) receive, as input data, information for a given individual and (ii) based on an evaluation of the received input data, output an efficacy prediction for the given individual.

Abstract: An example embodiment may involve (i) receiving, by a server device, deoxyribonucleic acid (DNA) information associated with a user; (ii) parsing, by the server device, the DNA information to identify one or more single nucleotide polymorphisms (SNPs)—(iii) determining, by the server device and based, on the identified SNPs, an endocannabinoid genotype of the user; (iv) determining, based on the endocannabinoid genotype of the user, a recommendation of one or more cannabinoid formulations; (v) transmitting, to a client device associated with the user, a web-based representation of a first graphical user interface; and (vi) receiving, from the client device, an indication to display a detailed representation of a particular cannabinoid formulation of the one or more cannabinoid formulations.

Abstract: The disclosure is directed to formulations comprising cannabinoids. More particularly, the cannabinoid formulations can be designed to align with an individual's genotype based on a defined list of polymorphisms.

Abstract: A radio receiver 1 has a device for reducing interference in an r.f. received signal, for example an HF signal conveying high speed data, including a channel estimator 3 for estimating the transmitted signal by comparing the received signal with locally generated signals processed in dependence on the response of the communication channel, together with a filter 2 for filtering interfering signals from the received signal. The use of the channel estimator for compensating for the response of the communication channel as opposed to an equaliser enables interfering signals to be filtered from the received signal.